# A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

> **NCT02362958** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 159 (actual)

## Conditions studied

- HER2 Positive Breast Cancer

## Interventions

- **DRUG:** lapatinib and capecitabine or vinorelbine

## Key facts

- **NCT ID:** NCT02362958
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-09
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02362958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02362958, "A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02362958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*